EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed Inc. (www.kinemed.com) announced today that Marc Hellerstein MD PhD, Co-Founder and Chief of the Scientific Advisory Board, will present “Proteome Dynamics: Measuring the Kinetics of Complex Networks in Cardiometabolic Disease” at the Kern Lipid Conference, July 12-15th at the Vail Cascade Resort, in Vail, Colorado. Dr. Hellerstein’s presentation will take place at 5:10 PM on July 12th as part of the Global Analyses of Lipids Session on the 2nd Floor, Centennial Ballroom D, Vail Cascade Conference Center.
Dr. Hellerstein will discuss KineMed's recent breakthroughs in the measurement of proteome dynamics, both global and targeted. These proprietary technical advances are leading to new predictive biomarkers that are directly translatable into man and apply to a variety of medical disorders. In addition, the presentation will describe KineMed's "virtual biopsy" technique, wherein labeled protein released from a cell of interest is isolated from an accessible body fluid (plasma, urine, or CSF). The labeling pattern in the protein reveals its dynamics back in the tissue. Applications of this novel approach will be discussed.
Rates of synthesis, breakdown, transport and secretion of hundreds of proteins simultaneously identify the kinetic signatures of diseases -- including cancer, metabolic, fibrotic and neurodegenerative diseases. Rates for targeted protein kinetics provide functionally interpretable metrics of disease activity, subtype, or therapeutic response. Dr. Hellerstein will share examples of recent successes in lipids / atherosclerosis, neurobiology, fibro-inflammatory disease, cancer and metabolic disease.
"The ability to interrogate global proteome dynamics in vivo in humans opens up nearly unlimited possibilities for biomarker discovery,” said Dr. Hellerstein, “Combined with the virtual biopsy concept, the causal processes inside cells that drive disease progression or reversal are for the first time becoming accessible to direct measurement in people."
About KineMed, Inc.
KineMed, Inc. is a biomarker discovery and development company based in Emeryville, California. Our biomarkers provide predictive, actionable information to dramatically improve, de-risk and accelerate drug discovery, development and disease management decisions.
We assist pharmaceutical collaborators by revealing the mechanism of action of complex diseases and providing quantitative measures of the effects of drugs on these causal processes. KineMed’s biomarkers are uniquely translational from preclinical to clinical settings, and further apply to both the diagnosis and management of disease.
KineMed’s neuro-biomarker platform applies to every phase of the CNS drug development life cycle:
- Candidate selection (Pre-Clinical/Discovery): Direct measurement of candidate effect on pathology
- First-in-human studies (Phase 1a and 1b): Reduction of risk in pre-clinical to clinical translation
- Proof of concept studies (Phase 2a): Reducing the time taken to reach an endpoint
- Efficacy studies (Phase 3): Patient selection to maximize delta
- Post-launch studies (Phase 4): Monitoring of efficacy
KineMed is seeking further broad collaborations with foundations, pharmaceutical, CRO, diagnostics, medical instruments and biotechnology partners in the CNS area.
For more information about KineMed, please visit: http://www.kinemed.com
About the Kern Lipid Conference
The 2012 Kern Lipid Conference will be held in Vail, Colorado, July 12-15th, 2012, at the Vail Cascade Resort and is entitled Systems Biology, Lipidomics and Cardiometabolic Diseases. The Conference aims to promote science that relates to the broad areas of lipid, cholesterol, bile acid and lipoprotein metabolism and the pathobiologies associated with disordered lipid metabolism.
The first Conference was held in 1985 to promote science relating to the broad areas of lipid, cholesterol, bile acid and lipoprotein metabolism. In 1996, to honor the legacy of Fred Kern, Jr., the conference was renamed to The Kern Aspen Lipid Conference by a unanimous vote of the Board of Directors. The emphasis of the Conference is to provide an open forum where scientists from both academia and industry can meet and discuss science related to lipid metabolism.
For more information, please visit: http://www.kernconference.org